Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 15, 2025
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors
Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology
Read more at globenewswire.com
